Bandaríkin - enska - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline tablets are contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of rasagiline tablets and initiation of treatment with these medications. rasagiline tablets are contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline tablets are contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. there are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to preg

Kanada - enska - Health Canada

angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors

Kanada - enska - Health Canada

angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors

Ísrael - enska - Ministry of Health

trima israel pharmaceutical products maabarot ltd - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Írland - enska - HPRA (Health Products Regulatory Authority)

apotex europe b.v. - rasagiline mesilate - tablets - 1 milligram - rasagiline

Ísrael - enska - Ministry of Health

teva israel ltd - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Ísrael - enska - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Ísrael - enska - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Kanada - enska - Health Canada

ascend laboratories ltd - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors

Kanada - enska - Health Canada

ascend laboratories ltd - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors